
Jean-Philippe Guilloux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7651496/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neurogenesis-Dependent and -Independent Effects of Fluoxetine in an Animal Model of Anxiety/Depression. Neuron, 2009, 62, 479-493.	3.8	1,080
2	Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature, 2005, 436, 103-107.	13.7	548
3	Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Molecular Psychiatry, 2012, 17, 1130-1142.	4.1	311
4	Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: Relevance to emotionality and sex. Journal of Neuroscience Methods, 2011, 197, 21-31.	1.3	242
5	Brain-Derived Neurotrophic Factor Signaling and Subgenual Anterior Cingulate Cortex Dysfunction in Major Depressive Disorder. American Journal of Psychiatry, 2012, 169, 1194-1202.	4.0	221
6	Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology, 2008, 55, 1006-1014.	2.0	136
7	Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology, 2013, 73, 147-159.	2.0	108
8	Learning and memory impairments in a neuroendocrine mouse model of anxiety/depression. Frontiers in Behavioral Neuroscience, 2014, 8, 136.	1.0	96
9	Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice. Journal of Neuroscience, 2016, 36, 518-531.	1.7	94
10	Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. International Journal of Neuropsychopharmacology, 2012, 15, 321-335.	1.0	91
11	Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. European Journal of Neuroscience, 2009, 30, 397-414.	1.2	78
12	Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice. PLoS ONE, 2010, 5, e9777.	1.1	78
13	Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease. Pharmaceuticals, 2016, 9, 9.	1.7	71
14	Blockade of 5-HT1A Receptors by (±)-Pindolol Potentiates Cortical 5-HT Outflow, but not Antidepressant-Like Activity of Paroxetine: Microdialysis and Behavioral Approaches in 5-HT1A Receptor Knockout Mice. Neuropsychopharmacology, 2006, 31, 2162-2172.	2.8	63
15	Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. Journal of Neurochemistry, 2004, 89, 54-63.	2.1	60
16	Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression. Neuropsychopharmacology, 2015, 40, 701-710.	2.8	58
17	Molecular and Genetic Characterization of Depression: Overlap with Other Psychiatric Disorders and Aging. Molecular Neuropsychiatry, 2015, 1, 1-12.	3.0	56
18	A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. European Journal of Pharmacology, 2010, 628, 83-90.	1.7	55

#	Article	IF	CITATIONS
19	Anticipated Brain Molecular Aging in Major Depression. American Journal of Geriatric Psychiatry, 2013, 21, 450-460.	0.6	53
20	Consequences of changes in BDNF levels on serotonin neurotransmission, 5-HT transporter expression and function: Studies in adult mice hippocampus. Pharmacology Biochemistry and Behavior, 2008, 90, 174-183.	1.3	50
21	Rapid and precise method to locate microdialysis probe implantation in the rodent brain. Journal of Neuroscience Methods, 2004, 140, 53-57.	1.3	49
22	Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice. Psychopharmacology, 2012, 220, 1-14.	1.5	49
23	S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms. Frontiers in Pharmacology, 2017, 8, 462.	1.6	47
24	Chronic corticosterone administration effects on behavioral emotionality in female c57bl6 mice Experimental and Clinical Psychopharmacology, 2017, 25, 94-104.	1.3	45
25	Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. Journal of Affective Disorders, 2015, 175, 233-240.	2.0	44
26	The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature. L'Encephale, 2016, 42, 156-164.	0.3	44
27	Characterization of 5-HT1A/1Bâ^'/â^' mice: An animal model sensitive to anxiolytic treatments. Neuropharmacology, 2011, 61, 478-488.	2.0	38
28	Altered Gene Synchrony Suggests a Combined Hormone-Mediated Dysregulated State in Major Depression. PLoS ONE, 2010, 5, e9970.	1.1	38
29	Substance P Neurokinin 1 Receptor Activation within the Dorsal Raphe Nucleus Controls Serotonin Release in the Mouse Frontal Cortex. Molecular Pharmacology, 2007, 72, 1411-1418.	1.0	36
30	Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review. Fundamental and Clinical Pharmacology, 2009, 23, 23-42.	1.0	36
31	Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT1A and 5-HT1B receptors disruption in mice. Neuroscience Letters, 2012, 521, 20-25.	1.0	34
32	Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. Neuropharmacology, 2016, 105, 142-153.	2.0	32
33	S 38093, a histamine H3 antagonist/inverse agonist, promotes hippocampal neurogenesis and improves context discrimination task in aged mice. Scientific Reports, 2017, 7, 42946.	1.6	29
34	Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety/Depression. Frontiers in Cellular Neuroscience, 2017, 11, 237.	1.8	29
35	Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety/depression. Neuroscience Letters, 2016, 616, 197-203.	1.0	23
36	Vortioxetine for the treatment of major depressive disorder. Expert Review of Clinical Pharmacology, 2014, 7, 731-745.	1.3	22

#	Article	IF	CITATIONS
37	NREM sleep hypersomnia and reduced sleep/wake continuity in a neuroendocrine mouse model of anxiety/depression based on chronic corticosterone administration. Neuroscience, 2014, 274, 357-368.	1.1	19
38	Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments. Psychopharmacology, 2016, 233, 3297-3314.	1.5	18
39	Optogenetic activation of granule cells in the dorsal dentate gyrus enhances dopaminergic neurotransmission in the Nucleus Accumbens. Neuroscience Research, 2018, 134, 56-60.	1.0	11
40	Targeted In Vivo Expression of Nicotinic Acetylcholine Receptors in Mouse Brain Using Lentiviral Expression Vectors. Journal of Molecular Neuroscience, 2006, 30, 105-106.	1.1	10
41	Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. Frontiers in Pharmacology, 2018, 9, 204.	1.6	8
42	Network analysis of positional candidate genes of schizophrenia highlights…more than… myelin-related pathways. Molecular Psychiatry, 2010, 15, 786-788.	4.1	7
43	A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). Archives of Cardiovascular Diseases, 2008, 101, 723-735.	0.7	6
44	Anticipated Brain Molecular Aging in Major Depression. American Journal of Geriatric Psychiatry, 2012, , 1.	0.6	2